For human CD34+ CML cells, BCR-ABLp210 knockdown achieves partial inhibition of BCR-ABLp210 activity and the addition of dasatinib completely inhibited the phosphorylation of CrkL and STAT5. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.